The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 ‘CREATE’
Titel:
The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 ‘CREATE’
Auteur:
Schöffski, Patrick Wozniak, Agnieszka Leahy, Michael G. Aamdal, Steinar Rutkowski, Piotr Bauer, Sebastian Richter, Stephan Grünwald, Viktor Debiec-Rychter, Maria Sciot, Raf Geoerger, Birgit Marréaud, Sandrine Collette, Sandra Nzokirantevye, Axelle Strauss, Sandra J.